Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 9.88%
Shs Outstand 40.69M
Perf Week -2.64%
Market Cap 623.36M
Forward P/E -
EPS next Y -0.78
Insider Trans -2.46%
Shs Float 37.13M
Perf Month -0.66%
Income -43.12M
PEG -
EPS next Q -0.27
Inst Own 92.06%
Short Float 7.60%
Perf Quarter -28.36%
Sales 144.04M
P/S 4.33
EPS this Y 15.66%
Inst Trans -0.55%
Short Ratio 6.01
Perf Half Y -13.30%
Book/sh 4.03
P/B 3.75
EPS next Y 17.67%
ROA -23.13%
Short Interest 2.82M
Perf Year -39.21%
Cash/sh 3.83
P/C 3.95
EPS next 5Y 8.90%
ROE -33.23%
52W Range 13.96 - 29.51
Perf YTD -27.92%
Dividend Est. -
P/FCF -
EPS past 5Y 12.47%
ROI -21.26%
52W High -48.73%
Beta 1.28
Dividend TTM -
Quick Ratio 8.75
Sales past 5Y 20.39%
Gross Margin 78.10%
52W Low 8.38%
ATR (14) 0.68
Dividend Ex-Date -
Current Ratio 9.76
EPS Y/Y TTM 32.27%
Oper. Margin -33.10%
RSI (14) 49.34
Volatility 4.72% 4.49%
Employees 344
Debt/Eq 0.23
Sales Y/Y TTM 23.46%
Profit Margin -29.93%
Recom 1.00
Target Price 25.56
Option/Short Yes / Yes
LT Debt/Eq 0.23
EPS Q/Q 16.38%
Payout -
Rel Volume 0.63
Prev Close 15.11
Sales Surprise 3.77%
EPS Surprise 12.54%
Sales Q/Q 15.77%
Earnings May 06 AMC
Avg Volume 469.71K
Price 15.13
SMA20 1.37%
SMA50 -2.85%
SMA200 -19.44%
Trades
Volume 294,757
Change 0.13%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated
Piper Sandler
Overweight
$25
Oct-12-22 Initiated
Jefferies
Buy
$20
Apr-07-22 Resumed
Cantor Fitzgerald
Overweight
$34
Jun-08-21 Initiated
Citigroup
Buy
$40
Mar-09-21 Reiterated
Needham
Buy
$35 → $34
Dec-16-20 Reiterated
Needham
Buy
$28 → $35
Aug-04-20 Reiterated
Needham
Buy
$22 → $24
Jun-16-20 Resumed
Cantor Fitzgerald
Overweight
$25
May-05-20 Reiterated
Needham
Buy
$27 → $22
Feb-19-20 Initiated
Needham
Buy
$27
Jan-08-20 Initiated
SunTrust
Buy
$27
Dec-18-19 Initiated
Cantor Fitzgerald
Overweight
$27
Nov-12-18 Initiated
Morgan Stanley
Overweight
$24
Nov-12-18 Initiated
JMP Securities
Mkt Outperform
$27
Nov-12-18 Initiated
Canaccord Genuity
Buy
$25
Nov-12-18 Initiated
BofA/Merrill
Buy
$23
Show Previous Ratings
May-07-24 11:16AM
09:00AM
08:04AM
(Thomson Reuters StreetEvents)
03:08AM
May-06-24 05:25PM
04:24PM
Loading…
04:24PM
(Associated Press Finance)
04:09PM
Apr-29-24 10:00AM
09:00AM
Apr-15-24 04:09PM
Mar-04-24 04:09PM
Feb-27-24 06:49AM
(Thomson Reuters StreetEvents) -13.53%
Feb-26-24 05:38PM
(Associated Press Finance)
04:34PM
04:09PM
10:00AM
Loading…
Feb-19-24 10:00AM
Feb-05-24 04:09PM
Jan-30-24 08:30AM
Jan-22-24 10:54AM
Jan-08-24 08:30AM
Jan-05-24 09:02AM
Nov-30-23 09:30AM
Nov-21-23 07:03AM
Nov-14-23 04:09PM
Nov-07-23 11:08AM
10:00AM
(Thomson Reuters StreetEvents)
Nov-06-23 05:38PM
(Associated Press Finance)
05:01PM
04:09PM
Nov-01-23 04:09PM
04:09PM
Loading…
Oct-16-23 04:09PM
Oct-09-23 12:00PM
Sep-08-23 09:40AM
Sep-06-23 09:55AM
Sep-05-23 04:09PM
Aug-29-23 04:09PM
Aug-09-23 10:07AM
Aug-08-23 06:23AM
(Thomson Reuters StreetEvents) -11.17%
Aug-07-23 05:20PM
04:09PM
Jul-19-23 04:09PM
Jul-17-23 04:09PM
Jul-06-23 10:00AM
May-29-23 10:15AM
May-24-23 04:09PM
May-04-23 10:29PM
04:09PM
12:00PM
May-02-23 02:12PM
10:33AM
(Thomson Reuters StreetEvents)
May-01-23 06:05PM
04:09PM
Apr-24-23 04:09PM
04:50AM
Apr-18-23 07:10AM
Apr-10-23 04:09PM
Mar-10-23 06:56AM
Mar-01-23 05:26AM
Feb-28-23 04:13PM
09:52AM
(Thomson Reuters StreetEvents)
Feb-27-23 05:35PM
04:09PM
Feb-20-23 10:00AM
Feb-06-23 04:09PM
Jan-09-23 09:00AM
Jan-03-23 04:09PM
Dec-27-22 08:30AM
Dec-01-22 09:01AM
Nov-07-22 05:35PM
04:09PM
Oct-31-22 10:00AM
Oct-17-22 04:04PM
Sep-11-22 09:22AM
Aug-29-22 09:55AM
Aug-23-22 08:02AM
Aug-11-22 09:55AM
Aug-08-22 05:35PM
04:02PM
Aug-04-22 10:00AM
Aug-01-22 10:01AM
Jul-19-22 01:34AM
Jul-18-22 08:00AM
08:00AM
Jun-13-22 08:00AM
Jun-12-22 09:15AM
May-31-22 08:00AM
May-15-22 08:14PM
May-09-22 05:25PM
04:02PM
May-05-22 05:35PM
May-04-22 06:25PM
May-02-22 03:00PM
Apr-19-22 08:00AM
Apr-18-22 04:03PM
08:00AM
Apr-04-22 01:35PM
Mar-16-22 06:00AM
Feb-28-22 04:02PM
Feb-01-22 08:00AM
Jan-10-22 07:00AM
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DUNN JEFFREY W Director May 02 '24 Sale 14.54 343 4,986 23,566 May 02 04:32 PM RECUPERO ANTHONY J President, Commercial Ops Apr 03 '24 Sale 15.63 920 14,379 251,533 Apr 04 07:59 PM RECUPERO ANTHONY J President, Commercial Ops Apr 02 '24 Sale 15.50 3,307 51,272 252,453 Apr 04 07:59 PM Maheshwari Anshul Chief Financial Officer Apr 02 '24 Sale 15.45 2,425 37,474 205,516 Apr 04 07:59 PM RECUPERO ANTHONY J President, Commercial Ops Mar 13 '24 Sale 16.82 3,330 56,023 255,760 Mar 14 05:46 PM Nishimura Mika Director Mar 13 '24 Sale 16.22 2,500 40,550 19,350 Mar 14 05:45 PM FRANCIS LAURA Chief Executive Officer Feb 16 '24 Sale 20.95 38,587 808,591 501,476 Feb 21 04:22 PM RECUPERO ANTHONY J President, Commercial Ops Feb 16 '24 Sale 20.95 7,822 163,910 259,090 Feb 21 04:20 PM Maheshwari Anshul Chief Financial Officer Feb 16 '24 Sale 20.96 7,336 153,726 207,941 Feb 21 04:20 PM DUNN JEFFREY W Director Feb 16 '24 Sale 20.95 4,160 87,173 40,223 Feb 21 04:21 PM DUNN JEFFREY W Director Feb 02 '24 Sale 20.30 335 6,799 44,383 Feb 05 07:53 PM Davis Timothy E JR Director Jan 02 '24 Option Exercise 3.24 21,111 68,400 43,472 Jan 09 06:01 PM Davis Timothy E JR Director Jan 02 '24 Sale 20.93 9,900 207,221 22,361 Jan 04 06:08 PM RECUPERO ANTHONY J President, Commercial Ops Jan 02 '24 Sale 20.93 1,936 40,511 198,903 Jan 04 06:07 PM Maheshwari Anshul Chief Financial Officer Jan 02 '24 Sale 20.92 1,470 30,758 147,268 Jan 04 06:06 PM RECUPERO ANTHONY J President, Commercial Ops Nov 17 '23 Sale 17.78 2,996 53,274 200,839 Nov 20 06:44 PM DUNN JEFFREY W Director Nov 16 '23 Sale 17.69 7,965 140,898 44,718 Nov 20 06:45 PM RECUPERO ANTHONY J President, Commercial Ops Nov 16 '23 Sale 17.69 5,461 96,582 203,835 Nov 20 06:44 PM Maheshwari Anshul Chief Financial Officer Nov 16 '23 Sale 17.59 1,733 30,478 148,738 Nov 20 06:43 PM DUNN JEFFREY W Director Nov 02 '23 Sale 17.52 406 7,113 52,683 Nov 06 07:12 PM DUNN JEFFREY W Director Oct 02 '23 Option Exercise 4.32 20,000 86,400 89,645 Oct 04 05:53 PM DUNN JEFFREY W Director Oct 02 '23 Sale 21.19 20,000 423,738 69,645 Oct 04 05:53 PM RECUPERO ANTHONY J President, Commercial Ops Oct 02 '23 Sale 21.16 1,712 36,222 209,296 Oct 04 05:52 PM Maheshwari Anshul Chief Financial Officer Oct 02 '23 Sale 21.15 1,244 26,310 150,471 Oct 04 05:51 PM DUNN JEFFREY W Director Sep 01 '23 Option Exercise 4.32 20,000 86,400 89,645 Sep 06 07:19 PM DUNN JEFFREY W Director Sep 01 '23 Sale 22.61 20,000 452,192 69,645 Sep 06 07:19 PM RECUPERO ANTHONY J President, Commercial Ops Aug 17 '23 Sale 21.07 2,997 63,147 211,008 Aug 18 04:13 PM FRANCIS LAURA Chief Executive Officer Aug 16 '23 Sale 20.96 9,012 188,900 437,039 Aug 18 04:12 PM DUNN JEFFREY W Director Aug 16 '23 Sale 20.99 7,964 167,126 69,645 Aug 18 04:11 PM RECUPERO ANTHONY J President, Commercial Ops Aug 16 '23 Sale 20.98 5,485 115,097 214,005 Aug 18 04:13 PM Maheshwari Anshul Chief Financial Officer Aug 16 '23 Sale 20.98 1,733 36,363 151,715 Aug 18 04:13 PM DUNN JEFFREY W Director Aug 11 '23 Option Exercise 4.32 20,000 86,400 97,609 Aug 15 05:17 PM DUNN JEFFREY W Director Aug 11 '23 Sale 21.48 20,000 429,634 77,609 Aug 15 05:17 PM Freund John Gordon Director Aug 09 '23 Sale 20.54 30,000 616,197 103,899 Aug 11 04:24 PM DUNN JEFFREY W Director Aug 02 '23 Sale 25.08 406 10,181 77,609 Aug 03 07:00 PM RECUPERO ANTHONY J President, Commercial Ops Jul 03 '23 Sale 26.68 1,712 45,684 219,490 Jul 05 06:11 PM Maheshwari Anshul Chief Financial Officer Jul 03 '23 Sale 26.70 1,244 33,219 153,448 Jul 05 06:13 PM HILLEMAN JERYL L Director Jun 20 '23 Sale 28.00 2,081 58,268 15,349 Jun 20 06:02 PM HILLEMAN JERYL L Director Jun 15 '23 Sale 28.74 2,081 59,808 17,430 Jun 20 06:02 PM RECUPERO ANTHONY J President, Commercial Ops Jun 15 '23 Sale 28.59 48 1,372 221,202 Jun 20 06:04 PM Maheshwari Anshul Chief Financial Officer Jun 07 '23 Sale 28.00 3,272 91,616 154,692 Jun 09 05:11 PM
Index -
P/E -
EPS (ttm) -1.81
Insider Own 9.96%
Shs Outstand 107.08M
Perf Week 37.45%
Market Cap 2.39B
Forward P/E -
EPS next Y -1.76
Insider Trans -0.10%
Shs Float 96.89M
Perf Month 83.98%
Income -192.74M
PEG -
EPS next Q -0.41
Inst Own 83.64%
Short Float 5.82%
Perf Quarter 39.17%
Sales 525.66M
P/S 4.54
EPS this Y 15.93%
Inst Trans 2.95%
Short Ratio 4.15
Perf Half Y 73.20%
Book/sh 3.34
P/B 6.64
EPS next Y -7.26%
ROA -16.79%
Short Interest 5.64M
Perf Year -72.51%
Cash/sh 8.12
P/C 2.73
EPS next 5Y -
ROE -48.70%
52W Range 10.87 - 83.60
Perf YTD 48.49%
Dividend Est. -
P/FCF -
EPS past 5Y -22.97%
ROI -20.19%
52W High -73.48%
Beta 0.80
Dividend TTM -
Quick Ratio 5.99
Sales past 5Y 17.16%
Gross Margin 74.97%
52W Low 103.96%
ATR (14) 1.10
Dividend Ex-Date -
Current Ratio 6.26
EPS Y/Y TTM -34.69%
Oper. Margin -39.07%
RSI (14) 86.30
Volatility 8.47% 6.47%
Employees 1453
Debt/Eq 1.66
Sales Y/Y TTM 0.61%
Profit Margin -36.67%
Recom 2.14
Target Price 25.50
Option/Short Yes / Yes
LT Debt/Eq 1.66
EPS Q/Q 28.06%
Payout -
Rel Volume 1.20
Prev Close 21.05
Sales Surprise 5.37%
EPS Surprise 14.29%
Sales Q/Q 13.36%
Earnings May 02 BMO
Avg Volume 1.36M
Price 22.17
SMA20 52.35%
SMA50 53.57%
SMA200 36.60%
Trades
Volume 1,633,139
Change 5.32%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed
JP Morgan
Neutral
$15
Aug-28-23 Downgrade
H.C. Wainwright
Buy → Neutral
$85 → $25
Aug-08-23 Upgrade
Piper Sandler
Neutral → Overweight
$45
Aug-04-23 Initiated
SVB Securities
Outperform
$51
Jul-31-23 Upgrade
Evercore ISI
Underperform → In-line
$33
Jun-07-23 Upgrade
Wedbush
Underperform → Neutral
$53 → $46
May-16-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$70 → $104
Mar-17-23 Downgrade
JP Morgan
Neutral → Underweight
$99 → $50
Jan-06-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$89 → $107
Jan-05-23 Reiterated
H.C. Wainwright
Buy
$100 → $140
Nov-29-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$74 → $89
Oct-24-22 Downgrade
Piper Sandler
Overweight → Neutral
$90 → $70
Jul-05-22 Downgrade
Evercore ISI
In-line → Underperform
May-16-22 Initiated
H.C. Wainwright
Buy
$115
Feb-08-22 Initiated
Loop Capital
Buy
$200
Feb-02-22 Upgrade
Oppenheimer
Perform → Outperform
$98
Jan-20-22 Upgrade
Truist
Hold → Buy
$125
Jan-03-22 Upgrade
Evercore ISI
Underperform → In-line
$82
Jul-01-21 Downgrade
Mizuho
Buy → Neutral
Apr-14-21 Downgrade
Wedbush
Neutral → Underperform
$159 → $154
Show Previous Ratings
May-14-24 07:08AM
May-10-24 05:14PM
May-03-24 12:08PM
01:00AM
May-02-24 01:19PM
11:56AM
Loading…
11:56AM
08:45AM
08:25AM
07:28AM
(Associated Press Finance)
07:01AM
07:00AM
Apr-25-24 10:01AM
Apr-24-24 10:45AM
Apr-05-24 07:00AM
Apr-04-24 11:33AM
12:00PM
Loading…
Apr-01-24 12:00PM
07:00AM
Mar-30-24 06:34AM
Mar-28-24 11:50AM
05:01AM
Mar-27-24 04:08PM
(Investor's Business Daily) +12.01%
09:29AM
09:16AM
(Investor's Business Daily)
07:14AM
07:12AM
07:05AM
07:00AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
12:15PM
Loading…
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
(Associated Press Finance)
07:00AM
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
(Associated Press Finance)
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
(Investor's Business Daily)
02:19PM
(Investor's Business Daily)
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 04 '24 Sale 16.01 1,217 19,484 251,235 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 04 '24 Sale 16.01 840 13,448 160,098 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 01 '24 Sale 16.03 2,107 33,769 252,452 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 01 '24 Sale 16.03 1,679 26,909 160,938 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Feb 28 '24 Sale 16.14 2,303 37,177 254,559 Feb 29 04:28 PM Leonard Frank X EVP, Pres., Novocure Oncology Feb 28 '24 Sale 16.14 2,078 33,545 162,617 Feb 29 04:38 PM Shah Pritesh Chief Growth Officer Nov 07 '23 Sale 12.65 382 4,832 124,511 Nov 08 04:22 PM Cordova Ashley Chief Financial Officer Nov 02 '23 Option Exercise 11.46 175 2,006 117,618 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Oct 31 '23 Option Exercise 9.58 17,793 170,447 117,443 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Sep 01 '23 Sale 21.82 883 19,265 99,650 Sep 05 04:24 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Sep 01 '23 Sale 21.82 294 6,414 209,825 Sep 05 04:24 PM Shah Pritesh Chief Growth Officer Sep 01 '23 Sale 21.82 273 5,956 124,893 Sep 05 04:23 PM Cordova Ashley Chief Financial Officer Aug 02 '23 Sale 30.25 1,144 34,607 100,533 Aug 04 04:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite